2024-11-05 - Analysis Report
## Merck & Co. Inc. (MRK) Stock Analysis

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription drugs, vaccines, and animal health products.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return (MRK):** 58.02%
* **Cumulative Return (VOO):** 131.78%
* **Difference:** -73.76%
* **Relative Divergence:** 11.92% (This means that MRK's performance is currently in the 11.92 percentile of its historical performance relative to VOO.)

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|------|
| 2015 | -11.2% | 18.1% | -11.6% | 1.0 |
| 2016 | 11.1% | 8.7% | 0.1% | 0.9 |
| 2017 | -7.0% | 17.0% | -25.8% | 0.5 |
| 2018 | 33.4% | 12.6% | 44.7% | 0.7 |
| 2019 | 22.7% | 12.1% | -8.3% | 0.7 |
| 2020 | -18.8% | 27.2% | -38.1% | 0.7 |
| 2021 | -2.7% | 19.8% | -44.7% | 0.3 |
| 2022 | 53.2% | 10.4% | 99.4% | 0.3 |
| 2023 | -7.5% | 14.0% | -43.0% | 0.2 |
| 2024 | -21.6% | 22.4% | -56.8% | 0.2 |

**Analysis:**

* MRK has significantly underperformed VOO over the long term, with a negative difference in cumulative returns. 
* The stock's Alpha has been volatile, indicating that it has not consistently outperformed the market. 
* The Beta has been decreasing, suggesting that MRK's price movements are becoming less sensitive to market fluctuations.

**2. Recent Price Movement:**

* **Closing Price:** 101.88 (Last-market: 101.17)
* **5-day Moving Average:** 103.4
* **20-day Moving Average:** 107.14
* **60-day Moving Average:** 112.63

**Analysis:**

* The stock is trading below its 5, 20, and 60-day moving averages, indicating a downtrend.
* The last-market price of 101.17 suggests a potential dip, although it's not significantly different from the closing price to indicate a major move.

**3. Technical Indicators:**

* **RSI:** 23.6
* **PPO:** -0.35
* **Delta_Previous_Relative_Divergence:** -10.21 (-)
* **Expected Return:** 0.0%

**Analysis:**

* The RSI is below 30, suggesting that the stock is oversold.
* The PPO is negative, indicating a downtrend.
* The negative Delta_Previous_Relative_Divergence indicates a short-term downward momentum.
* The Expected Return is 0%, indicating a lack of significant outperformance potential compared to VOO.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

**Analysis:**

* The latest earnings report on 2024-08-05 showed an EPS of 2.15, exceeding analyst expectations.
* The company's revenue has been relatively stable, with a slight uptick in the last quarter.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---|---|---|
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |
| 2023-06-30 | $15.04B | 73.24% |

**Capital and Profitability:**

| Quarter  | Equity     | ROE |
|---|---|---|
| 2024-06-30 | $43.58B  | 12.52% |
| 2024-03-31 | $40.36B  | 11.80% |
| 2023-12-31 | $37.58B  | -3.26% |
| 2023-09-30 | $41.25B  | 11.50% |
| 2023-06-30 | $38.69B | -15.44% |

**Analysis:**

* MRK has maintained a strong profitability margin. 
* The company's ROE has been fluctuating, with negative returns in two recent quarters, possibly due to economic conditions or specific business decisions.

**6. News and Recent Issues:**

* **Recent Earnings Announcement:** The latest earnings report for Q2 2024 was released on 2024-08-05, exceeding analyst expectations. 
* **Market Outlook:** According to FINBOLD, MRK has a “Neutral” market outlook, with analysts highlighting the company’s strong financial position and pipeline of new drugs. However, there are concerns about potential competition and the current economic environment impacting growth.
* **Analyst Opinions:** Analysts generally remain optimistic about MRK's long-term potential, citing its strong brand reputation and robust product portfolio. However, some analysts are cautious about near-term performance due to the challenging market conditions.

**7. Overall Analysis:**

MRK is a well-established pharmaceutical company with a strong track record of profitability and a promising product pipeline. However, the stock has underperformed the market in recent years, and technical indicators suggest a short-term downtrend. The company's earnings performance has been steady, but concerns remain about future growth potential in the current market environment.

**8. Recommendations:**

Given the current situation, MRK may not be the best investment choice for short-term gains. However, for long-term investors with a high-risk tolerance, MRK could be an attractive option due to its potential for growth and its strong financial foundation. It's essential to monitor the company's future earnings reports, market conditions, and analyst opinions to make a well-informed decision.

**Note:** This analysis is based on the provided data and publicly available information. It should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions.